Clincosm LogoSign in Get a demo

Bioequivalence of Phenazopyridine HCl in Healthy Volunteers

Sponsor
Universal Enterprises (Industry)
Overall Status
Unknown status
CT.gov ID
NCT00743977
Collaborator
(none)
24
Enrollment
1
Location
2
Arms

Study Details

Study Description

Brief Summary

The present study aims at comparing the pharmacokinetics of the original formulation of phenazopyridine and a same generic product.

Condition or Disease Intervention/Treatment Phase
  • Drug: Phenazopyridine HCl
 N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
24 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Participant)
Primary Purpose:
Basic Science
Official Title:
2 Treatment, 2 Period, Randomized, Single Blinded, Crossover Bioequivalence of Phenazopyridine HCl in 24 Healthy Volunteers
Study Start Date :
Aug 1, 2008
Anticipated Primary Completion Date :
Nov 1, 2008

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: A

Drug: Phenazopyridine HCl
100mg tablet in fasting state
Other Names:
  • Pyridium

    		•
    Experimental: B

    Drug: Phenazopyridine HCl
    100mg tablet in fasting state
    Other Names:
  • Pyridium

    		•

    Outcome Measures

    Primary Outcome Measures

    1. The primary outcome of the study will be to determine the bioequivalence of both the formulations of phenazopyridine [regular intervals after drug dosing]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 55 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    • Healthy subjects aged 18 to 55 (Male & Female)

    • Physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, laboratory tests

    • Informed consent signed by the subject

    • The subject is co-operative and available for the entire study

    • Not pregnant or nursing

    • Normal renal and hepatic function

    Exclusion Criteria:

    • Evidence in the subject medical history or in the medical examination of any clinically significant hepatic, renal, gastrointestinal, cardiovascular, pulmonary, hematological or other significant acute or chronic abnormalities which might influence either the safety of the subject or the absorption, distribution, metabolism or excretion of the active agent under investigation

    • Hypersensitivity to subject drug, atopic eczema or allergic bronchial asthma

    • Evidence of hypertension (blood pressure after 3 minutes sitting>160/95 mm Hg)

    • Evidence of chronic or acute infectious diseases;

    • History or evidence of malignant tumors;

    • Evidence of hyperuricaemia, elevated serum uric acid (>8.0 mg/dl)

    • Hepatic or renal impairment; elevated serum creatinine (>1.4 mg/dl)

    • Planned vaccination during the time course of the study

    • Adherence to a diet (i.e, vegetarian) or life style (incl. extreme sports) that might interfere with the investigation

    • Laboratory test results outside the tolerance values as laid down by the study centre, which may be an evidence of disease. Positive result of HIV1/2, HCV antibody or HBs antigen testing

    • Regular use of any medication within four weeks prior to commencement of the study (self-medication or prescription)

    • Single use of any medication (including OTC) that are not expressively permitted within two weeks prior to start of the study

    • Abuse of alcohol, caffeine or tobacco (equivalent to more than 10 cigarettes a day)

    • Drug addiction

    • Participation in a clinical investigation or blood donation of more than 250 ml within the past eight weeks or blood donation of less than 250 ml within the past 4 week

    • Subjects who are known or suspected

    • not to comply with the study directives

    • not to be reliable or trustworthy

    • not to be capable of understanding and evaluating the information given to them as part of the formal information policy (informed consent),in particular regarding the risks and discomfort to which they would agree to be exposed.

    • to be in such a precarious financial situation that they no longer weigh up the possible risks of their participation and the unpleasantness they may be involved in.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Health Care Hospital Karachi Pakistan

    Sponsors and Collaborators

    • Universal Enterprises

    Investigators

    • Principal Investigator: Waqar H. Kazmi, M.D, M.S.,

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00743977
    Other Study ID Numbers:
    • URG/STEROP/001
    First Posted:
    Aug 29, 2008
    Last Update Posted:
    Aug 29, 2008
    Last Verified:
    Aug 1, 2008

    Study Results

    No Results Posted as of Aug 29, 2008